HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Levinson, Pauline ^a   Choi, Robert Y ^b,c   Cole, Amy L ^d   Hirbod, Taha ^a   Rhedin, Samuel ^a   Payne, Barbara ^b,c   Guthrie, Brandon L ^c   Bosire, Rose ^b,e   Cole, Alexander M ^d   Farquhar, Carey ^c   Broliden, Kristina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; POLYPEPTIDE ANTIBIOTIC AGENT; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; PEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION RISK; KENYA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN DEPLETION; SCREENING; VAGINA SECRETION; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; PROSPECTIVE STUDY; SECRETION; UTERINE CERVIX MUCUS; VAGINA;

BACTERIA (MICROORGANISMS); HUMAN HERPESVIRUS 2;

CERVIX MUCUS; FEMALE; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; PEPTIDES; PROSPECTIVE STUDIES; VAGINA;

EID: 84857516380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031996     Document Type: Article

References (29)

1. Broliden K, (2010) Innate molecular and anatomic mucosal barriers against HIV infection in the genital tract of HIV-exposed seronegative individuals. J Infect Dis 202 (Suppl 3): S351-355.
2. Kaushic C, Ferreira VH, Kafka JK, Nazli A, (2010) HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment. Am J Reprod Immunol 63: 566-575.
3. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, et al. (2010) Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 5: e11366.
4. Valore EV, Park CH, Igreti SL, Ganz T, (2002) Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 187: 561-568.
5. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM, (2005) Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 175: 7560-7567.
6. Burgener A, Boutilier J, Wachihi C, Kimani J, Carpenter M, et al. (2008) Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 7: 4446-4454.
7. Iqbal SM, Ball TB, Kimani J, Kiama P, Thottingal P, et al. (2005) Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 192: 728-738.
8. Jendrysik MA, Ghassemi M, Graham PJ, Boksa LA, Williamson PR, et al. (2005) Human cervicovaginal lavage fluid contains an inhibitor of HIV binding to dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Infect Dis 192: 630-639.
9. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, et al. (2009) Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. Aids 23: 309-317.
10. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, et al. (2007) Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 14: 1102-1107.
11. Cole AM, Cole AL, (2008) Antimicrobial Polypeptides are Key Anti-HIV-1 Effector Molecules of Cervicovaginal Host Defense. Am J Reprod Immunol 59: 27-34.
12. Chang TL, Vargas J Jr, DelPortillo A, Klotman ME, (2005) Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115: 765-773.
13. Mackewicz CE, Yuan J, Tran P, Diaz L, Mack E, et al. (2003) alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17: F23-32.
14. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Soderlund J, (2007) The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res 5: 410-415.
15. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, et al. (2004) Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 200: 1337-1346.
16. Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, et al. (2009) The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS One 4: e5006.
17. Guthrie BL, Choi RY, Liu AY, Mackelprang RD, Rositch AF, et al. (2011) Barriers to Antiretroviral Initiation in HIV-1-Discordant Couples. J Acquir Immune Defic Syndr.
18. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, et al. (2000) Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 38: 2688-2695.
19. Macaluso M, Lawson L, Akers R, Valappil T, Hammond K, et al. (1999) Prostate-specific antigen in vaginal fluid as a biologic marker of condom failure. Contraception 59: 195-201.
20. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, et al. (2008) HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22: 727-735.
21. Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, et al. (2010) Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 5: e12598.
22. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, et al. (2000) Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14: 1917-1920.
23. Mitchell CM, Balkus J, Agnew KJ, Cohn S, Luque A, et al. (2008) Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses 24: 667-671.
24. Valore EV, Wiley DJ, Ganz T, (2006) Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun 74: 5693-5702.
25. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, et al. (2006) Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 13: 1111-1118.
26. Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, et al. (2011) Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. PLoS One 6: e20637.
27. Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK, et al. (2010) Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 63: 544-565.
28. Shattock RJ, Warren M, McCormack S, Hankins CA, (2011) AIDS. Turning the tide against HIV. Science 333: 42-43.
29. Pala P, Gomez-Roman VR, Gilmour J, Kaleebu P, (2009) An African perspective on mucosal immunity and HIV-1. Mucosal Immunol 2: 300-314.